Investigation of short-term efficacy and safety of 5-alpha reductase inhibitor in the patients with BPH

Investigation of short-term efficacy and safety of 5-alpha reductase inhibitor in the patients with BPH - Investigation of short-term efficacy and safety of 5-alpha reductase inhibitor in the patients with BPH

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025443

Enrollment

200

Registered

2016-12-27

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BPH

Interventions

Group 1: dutasteride + tamsulosin IPSS, VAS, uroflowmetry, PVR, and Prostate volume at week 1, 2, 4, 6, 8, 10, and 12 Group 2: tamsulosin only IPSS, VAS, uroflowmetry, PVR, and Prostate volume at we

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: BPH IPSS 8 and more Qmax 15 mL/s and more Prostate volume 30 mL and more

Exclusion criteria

Exclusion criteria: PSA 10ng/mL and more Prostate cancer Surgery for prostate in the last 3 months

Design outcomes

Primary

Measure	Time frame
Cost-effectiveness of dutasteride	—

Countries

Japan

Contacts

Public ContactKiyohide Fujimoto

Nara Medical University Urology

kiyokun@naramed-u.ac.jp0744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026